Fujian Cosunter Pharmaceutical Co Ltd is a China-based company principally engaged in the production and sale of pharmaceuticals. The Company's main products include Tenofovir alafenamide Fumarate Tablets, Entecavir Capsules, Lamivudine Tablets, Silybin Meglumine Tablets, Adefovir Dipivoxil Tablets, Ursodeoxycholic Acid Capsules, Tadalafil Tablets, Rivaroxaban Tablets and others. The Company's products are mainly used in the fields of anti-hepatitis B virus, liver health, men's health, cardiovascular treatment and others. The Company mainly operates its businesses in the domestic market.

Employees

Sector

Pharmaceuticals

Calendar

08-29 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-13	CN¥100.65	+2.48%	10,327,546
26-08-12	CN¥98.21	-2.38%	6,113,746
26-08-11	CN¥100.60	+4.03%	10,354,528
26-08-10	CN¥96.70	-0.19%	9,627,561
26-08-07	CN¥96.88	+4.48%	8,697,749

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. 2026-08-13			5-day change	1st Jan Change
100.65 ^CNY	+2.48%		+8.17%	+12.90%

06-17	Fujian Cosunter Pharmaceutical Gets Shenzhen Bourse Nod for 723 Million Yuan Private Share Placement	MT
06-16	Fujian Cosunter Pharmaceutical Gets Shenzhen Bourse Approval for Share Placement	MT

Market Cap	16.03B 2.38B 2.06B 1.93B 1.76B 3.31B 227B 3.37B 22.71B 8.88B 114B 8.93B 8.74B 380B	P/E 2024	-33.3x	P/E 2025	-65.2x
Enterprise Value	16.27B 2.42B 2.09B 1.96B 1.79B 3.36B 231B 3.42B 23.05B 9.01B 115B 9.07B 8.87B 385B	EV / Sales 2024	12.5x	EV / Sales 2025	34.7x
Free-Float	52.25%	Yield 2024 *	-	Yield 2025	-

06-17	Fujian Cosunter Pharmaceutical Gets Shenzhen Bourse Nod for 723 Million Yuan Private Share Placement	MT
06-16	Fujian Cosunter Pharmaceutical Gets Shenzhen Bourse Approval for Share Placement	MT
04-28	Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-28	Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-05	Fujian Cosunter Pharmaceutical Completes Patient Enrollment for Hepatitis B Drug Phase 3 Trial	MT
25-10-29	Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-09-25	Cosunter Pharma to Extend Equity Repurchase Commitment for Subsidiary	MT
25-09-21	Fujian Cosunter Pharmaceutical Co., Ltd.(XSEC:300436) added to S&P Global BMI Index	CI
25-09-16	Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. announced that it expects to receive CNY 191.351351 million in funding from Fujian Cosunter Pharmaceutical Co., Ltd.	CI
25-09-03	Two Investors to Own Stake in Fujian Cosunter Pharmaceutical's Unit for 191 Million Yuan	MT
25-08-22	Cosunter Pharma's H1 Loss Widens	MT
25-08-21	Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-11	Cosunter Pharmaceutical Wins Breakthrough Therapy Status for CHB Drug in China	MT

1 day	+2.48%
1 week	+8.17%
Current month	+13.50%
1 month	+2.30%
3 months	-13.05%
6 months	-21.34%
Current year	+12.90%

Fujian Cosunter Pharmaceutical Co., Ltd. Stock

Stocks

300436

CNE100001YZ0

Pharmaceuticals

Valuation: Fujian Cosunter Pharmaceutical Co., Ltd.

Chart: Fujian Cosunter Pharmaceutical Co., Ltd.

Latest news : Fujian Cosunter Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Fujian Cosunter Pharmaceutical Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	91.86	105.55
1 month	83.4	109.66
Current year	79	149
1 year	79	188.93
3 years	14.16	188.93
5 years	14.16	188.93
10 years	14.16	188.93

Manager	Title	Age	Since
Guo Ping Li CEO	Chief Executive Officer	58	2020-03-24
Jian Hui Guan DFI	Director of Finance/CFO	50	2017-07-24
Fu hu Huang COO	Chief Operating Officer	50	2025-01-12

Director	Title	Age	Since
Guo Ping Li CHM	Chairman	58	2001-06-27
Li Qing Ye BRD	Director/Board Member	56	2011-09-19
Guo Dong Li BRD	Director/Board Member	55	2001-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/6/23	Guo Ping Li	Sell	Chief Executive Officer	441,900	0.3316%
6/5/23	Guo Ping Li	Sell	Chief Executive Officer	376,100	0.2822%
5/22/23	Guo Ping Li	Sell	Chief Executive Officer	238,800	0.1792%

	2024	2025
Net sales	441M 65.54M 56.74M 53.25M 48.51M 91.13M 6.25B 92.83M 625M 244M 3.13B 246M 241M 10.45B	416M 61.81M 53.52M 50.23M 45.75M 85.95M 5.9B 87.56M 590M 231M 2.95B 232M 227M 9.86B
Net income	-156M -23.2M -20.09M -18.85M -17.17M -32.26M -2.21B -32.87M -221M -86.54M -1.11B -87.11M -85.22M -3.7B	-218M -32.34M -28M -26.28M -23.94M -44.97M -3.09B -45.81M -309M -121M -1.55B -121M -119M -5.16B
Net Debt	299M 44.33M 38.38M 36.02M 32.81M 61.64M 4.23B 62.79M 423M 165M 2.12B 166M 163M 7.07B	242M 35.93M 31.11M 29.2M 26.59M 49.96M 3.43B 50.9M 343M 134M 1.72B 135M 132M 5.73B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.	+2.48%	+8.17%	-25.56%	+270.45%	2.32B
ELI LILLY AND COMPANY	-0.92%	+3.35%	+89.07%	+128.86%	1,088B
JOHNSON & JOHNSON	+0.47%	+1.74%	+51.68%	+50.75%	629B
ABBVIE INC.	+0.83%	+1.88%	+26.27%	+64.82%	440B
ROCHE HOLDING AG	-0.88%	-0.66%	+47.04%	+36.64%	359B
NOVARTIS AG	-0.37%	-0.58%	+28.59%	+36.31%	291B
ASTRAZENECA PLC	+0.05%	-2.73%	+5.61%	+6.15%	245B
AMGEN INC.	+0.40%	+2.45%	+46.62%	+59.17%	225B
NOVO NORDISK A/S	-0.42%	+1.34%	-6.94%	-51.94%	204B
GILEAD SCIENCES, INC.	+1.67%	+4.84%	+15.10%	+72.68%	168B
Average	+0.47%	+1.53%	+27.75%	+67.39%	365.15B
Weighted average by Cap.	+0.30%	+1.93%	+49.04%	+66.10%